Your browser doesn't support javascript.
loading
Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis.
de Moreno de LeBlanc, Alejandra; Del Carmen, Silvina; Chatel, Jean-Marc; Azevedo, Vasco; Langella, Philippe; Bermudez-Humaran, Luis; LeBlanc, Jean Guy.
Afiliação
  • de Moreno de LeBlanc A; Centro de Referencia para Lactobacilos (CERELA-CONICET), San Miguel de Tucumán, Tucumán, Argentina.
  • Del Carmen S; Centro de Referencia para Lactobacilos (CERELA-CONICET), San Miguel de Tucumán, Tucumán, Argentina.
  • Chatel JM; INRA and AgroParisTech, UMR Micalis, Jouy-en-Josas, France.
  • Azevedo V; Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
  • Langella P; INRA and AgroParisTech, UMR Micalis, Jouy-en-Josas, France.
  • Bermudez-Humaran L; INRA and AgroParisTech, UMR Micalis, Jouy-en-Josas, France.
  • LeBlanc JG; Centro de Referencia para Lactobacilos (CERELA-CONICET), San Miguel de Tucumán, Tucumán, Argentina.
J Med Microbiol ; 65(9): 1038-1046, 2016 Sep.
Article em En | MEDLINE | ID: mdl-27469354
Inflammatory bowel diseases (IBDs) affect the gastrointestinal tract and are characterized by recurrent inflammation that requires lifelong therapies. Probiotics such as lactic acid bacteria (LAB) have been proposed to complement current treatment protocols for these patients; however, their characteristics are strain dependent. In this regard, certain novel characteristics are only possible through the genetic modification of these beneficial micro-organisms. Different delivery systems, such as protein delivery of anti-oxidant enzymes and anti-inflammatory cytokines, have been shown to be effective in preventing and treating IBD in animal models. In this study, the safety of the recombinant LAB (recLAB) Streptococcus thermophilus CRL807 : CAT, S. thermophilus CRL807 : SOD, Lactococcus lactis NCDO2118 pXILCYT : IL-10, L. lactis MG1363 pValac : IL-10 and L. lactis MG1363 pGroESL : IL-10 with proven beneficial effects was compared to their progenitor strains S. thermophilus CRL807, L. lactis NCDO2118 or L. lactis MG1363. The prolonged administration of these genetically modified strains showed that they were just as safe as the native strains from which they derive, as demonstrated by normal animal growth and relative organ weights, absence of microbial translocation from the gastrointestinal tract, normal blood parameters and intestinal histology. The results show the potential use of these recLAB in future therapeutic formulations; however, the use of modern bio-containment systems is required for the future acceptance of these recLAB by the medical community and patients with IBD.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Biológica / Lactococcus lactis / Colite / Probióticos / Streptococcus thermophilus / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Tipo de estudo: Guideline / Prognostic_studies Limite: Animals Idioma: En Revista: J Med Microbiol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Argentina País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Biológica / Lactococcus lactis / Colite / Probióticos / Streptococcus thermophilus / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos Tipo de estudo: Guideline / Prognostic_studies Limite: Animals Idioma: En Revista: J Med Microbiol Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Argentina País de publicação: Reino Unido